Results 201 to 210 of about 33,240 (248)

Fusion/entry inhibitors as therapies for HIV

Expert Opinion on Emerging Drugs, 2001
A combination of three or more antiretroviral drugs, commonly termed 'highly active antiretroviral therapy' (HAART), has become the standard-of-care treatment for HIV-related disease in the developed world. Since its initiation in the mid 1990s, HAART has led to substantial reductions in both mortality and morbidity.
Mike Westby
exaly   +3 more sources

Development of HIV fusion inhibitors

Journal of Peptide Science, 2005
AbstractIn the past 25 years, the worldwide AIDS epidemic has grown such that roughly 38 million people were estimated to be living with the disease worldwide at the end of 2003. The introduction of antiretroviral‐based therapies, beginning in 1987, has enabled many to live with HIV as a chronic, rather than terminal, disease.
Stephen E, Schneider, Brian L, Bray, Catherine J, Mader, Paul E, Friedrich, Mark W, Anderson, Tracy S, Taylor, Natalia, Boshernitzan, Toivo E, Niemi, Brian C, Fulcher, Sheila R, Whight, Jonathan M, White, Reagan J, Greene, Larry E, Stoltenberg, Maynard, Lichty   +13 more
exaly   +3 more sources

Development of HIV-1 Fusion Inhibitors Targeting gp41

Current Medicinal Chemistry, 2014
The HIV-1 envelope protein glycoprotein 41 (gp41) is crucial in the HIV-1 infection process, therefore gp41 has emerged as an attractive target for drug design against AIDS. During the past few decades, tremendous efforts have been made on developing inhibitors that can prevent the HIV-1 entry process via suppressing functional gp41.
Fangwei Shao
exaly   +5 more sources

Enfuvirtide: the first HIV fusion inhibitor

Expert Opinion on Pharmacotherapy, 2005
Highly active antiretroviral therapy, a combination of antiretrovirals to treat HIV-infected individuals, may fail for a number of reasons, including the selection of genetic mutations which confer resistance to the antiretroviral drugs, and poor adherence or treatment discontinuation resulting from drug toxicity.
Adriano Lazzarin
exaly   +3 more sources

Bivalent HIV-1 fusion inhibitors based on peptidomimetics

Bioorganic and Medicinal Chemistry, 2020
Membrane fusion is a valid target for inhibition of HIV-1 replication. A 34-mer fragment peptide (C34), which is contained in the HIV-1 envelope protein gp41, has significant anti-HIV activity. Previously, a dimeric derivative of C34 linked by a disulfide bridge at its C-terminus was found to have more potent anti-HIV activity than the C34 peptide ...
Takuya Kobayakawa, Hirokazu Tamamura, Kohei Tsuji   +2 more
exaly   +3 more sources

HIV fusion inhibitors

Reviews in Medical Virology, 2009
AbstractDrugs based on amino acid sequence of Heptad Repeats of gp41 of HIV have been explored in search of anti‐HIV drugs acting by inhibition of the gp41 6‐helix formation and subsequent cellular infection. These are classified under a distinct discipline called HIV fusion inhibitors.
M I, Qadir, S A, Malik
openaire   +2 more sources

Inhibition of HIV-1 by Fusion Inhibitors

Current Pharmaceutical Design, 2010
The envelope glycoprotein complex (Env) is responsible for entry of the human immunodeficiency virus type 1 (HIV-1) into cells by mediating attachment to target cells and subsequent membrane fusion. Env consists of three gp120 subunits that mediate receptor and co-receptor attachment and three gp41 subunits responsible for membrane fusion.
Dirk, Eggink, Ben, Berkhout, Rogier W, Sanders   +2 more
openaire   +3 more sources

Entry and fusion inhibitors of HIV

Expert Opinion on Therapeutic Patents, 2004
Considerable advances have been made towards finding compounds that are active as inhibitors of the entry and fusion of HIV. The discovery of chemokines a few years ago focused the attention on coreceptor inhibitors, in addition to fusion and attachment blockers.
S. Rusconi, E. Bulgheroni, P. Citterio
openaire   +1 more source

Inhibiting HIV-1 Entry with Fusion Inhibitors

Current Medicinal Chemistry, 2003
In recent years, tremendous progress has been made in understanding the HIV-1 entry process in which the viral and cellular membranes are fused, resulting in the subsequent delivery of the viral genome into the host cell. The mechanistic insight gained from these studies has led to the formulation of exciting new approaches for therapeutic intervention.
C E, Baldwin, R W, Sanders, B, Berkhout
openaire   +3 more sources

HIV entry and fusion inhibitors

Expert Opinion on Emerging Drugs, 2004
Human immunodeficiency virus (HIV) is a retrovirus that is the causative agent of acquired immunodeficiency syndrome (AIDS). Current HIV therapy is based on targeting two critical enzymes in the viral replication machinery: reverse transcriptase and a virally encoded protease. Although mortality rates due to HIV infection have been dramatically reduced,
openaire   +2 more sources